Compare Novo Nordisk A/S (NVO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tesla, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Tesla, Inc. trades at $379.4 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 6.3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| NVO | TSLA | |
|---|---|---|
Market Cap | $220.53B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $489.88 |
52-Week Low | $35.29 | $302.63 |
Enterprise Value | $239.49B | $1.36T |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Tesla (TSLA) trades at $378.88, down 0.51% with a bearish technical outlook. The stock faces valuation concerns with a P/E of 339 and declining profitability margins, though recent earnings beat expectations. Cash flow remains positive despite heavy capital investments. European regulatory approval for driver-assistance software and German sales growth provide optimism, but competition and slowing auto business present challenges.
Tesla's outlook balances innovation potential against execution risks. The stock offers growth exposure to AI and autonomy but carries premium valuation and competitive pressures. Near-term catalysts include Q2 earnings and robotaxi developments, while margin compression and market sentiment shifts represent key investor risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
